METUCHEN Company Profile
✉ Email this page to a colleague
What is the competitive landscape for METUCHEN, and what generic alternatives to METUCHEN drugs are available?
METUCHEN has one approved drug.
There is one US patent protecting METUCHEN drugs.
There are thirty-nine patent family members on METUCHEN drugs in twenty-five countries and eleven supplementary protection certificates in eleven countries.
Summary for METUCHEN
| International Patents: | 39 |
| US Patents: | 1 |
| Tradenames: | 1 |
| Ingredients: | 1 |
| NDAs: | 1 |
Drugs and US Patents for METUCHEN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Metuchen Pharms | STENDRA | avanafil | TABLET;ORAL | 202276-003 | Apr 27, 2012 | AB | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | ||||
| Metuchen Pharms | STENDRA | avanafil | TABLET;ORAL | 202276-001 | Apr 27, 2012 | AB | RX | Yes | No | ⤷ Subscribe | ⤷ Subscribe | ||||
| Metuchen Pharms | STENDRA | avanafil | TABLET;ORAL | 202276-002 | Apr 27, 2012 | AB | RX | Yes | No | 6,656,935 | ⤷ Subscribe | Y | Y | ⤷ Subscribe | |
| Metuchen Pharms | STENDRA | avanafil | TABLET;ORAL | 202276-001 | Apr 27, 2012 | AB | RX | Yes | No | 6,656,935 | ⤷ Subscribe | Y | Y | ⤷ Subscribe | |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for METUCHEN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Metuchen Pharms | STENDRA | avanafil | TABLET;ORAL | 202276-001 | Apr 27, 2012 | 7,501,409 | ⤷ Subscribe |
| Metuchen Pharms | STENDRA | avanafil | TABLET;ORAL | 202276-003 | Apr 27, 2012 | 7,501,409 | ⤷ Subscribe |
| Metuchen Pharms | STENDRA | avanafil | TABLET;ORAL | 202276-002 | Apr 27, 2012 | 7,501,409 | ⤷ Subscribe |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for METUCHEN drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Tablets | 50 mg, 100 mg and 200 mg | ➤ Subscribe | 2016-04-27 |
International Patents for METUCHEN Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Australia | 767558 | ⤷ Subscribe |
| Germany | 60034239 | ⤷ Subscribe |
| Israel | 148291 | ⤷ Subscribe |
| Canada | 2407231 | ⤷ Subscribe |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for METUCHEN Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1219609 | 2013/041 | Ireland | ⤷ Subscribe | PRODUCT NAME: AVANAFIL OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTRATION NO/DATE: EU/1/13/841 20130613 |
| 1219609 | CA 2013 00040 | Denmark | ⤷ Subscribe | |
| 1219609 | C300618 | Netherlands | ⤷ Subscribe | PRODUCT NAME: AVANAFIL; REGISTRATION NO/DATE: EU/1/13/841 20130621 |
| 1219609 | 2013C/051 | Belgium | ⤷ Subscribe | PRODUCT NAME: AVANAFIL; AUTHORISATION NUMBER AND DATE: EU/1/13/841 20130624 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
